Videos

Fred Saad, MD, FRCS, CQ, FCAHS, discussed the clinical benefits of introducing lutetium-177-PSMA-617 earlier to delay progression to mCRPC.

Leveraging 6-month PSA and PSMA-PET metrics may guide therapy escalation or de-escalation in metastatic hormone-sensitive prostate cancer.

Clinicians share practical tips to prevent amivantamab–lazertinib rash, streamline orders, manage edema, and use short-term DOAC prophylaxis.

Fedratinib may target various proliferative pathways in MDS/MPN that other current standards of care miss, according to Andrew Kuykendall, MD.

Findings from a study exploring how AI-driven NCCN guideline interpretation can optimize genetic testing and reduce clinician burden in prostate cancer.

The subcutaneous formulation of amivantamab may avoid infusion-related reactions reported with the agent’s intravenous form, said Joel W. Neal, MD, PhD.

Paolo Tarantino, MD, PhD, discussed how clinical aggressiveness, toxicity, and progression patterns guide the sequencing of ADCs in breast cancer care.

Nathan Goodyear, MD, MDH, broke down how findings from the CHALLENGE and OPTIMUS studies show that structured exercise may turn cold tumors hot.

Maurie Markman, MD, joins The Moonlight Shift to discuss precision medicine's real-world limits, oncology's cost crisis, CAR-T in solid tumors, and the decision support gap costing patients.

Nathan Goodyear, MD, outlined how exercise and nutrition can counter treatment-induced immunosenescence and improve long-term oncology outcomes.

Learn how proactive prophylaxis makes subcutaneous amivantamab plus lazertinib more tolerable, cutting severe rash, nail issues and clot risk.

Identifying patients early is key for getting them into the CAR T-cell therapy pipeline, according to Saad Z. Usmani, MD, MBA, FACP, FASCO.

Learn how monthly subcutaneous amivantamab cuts clinic time, eases infusion capacity, and supports dose tweaks without sacrificing outcomes.

Jesus D. Anampa, MD, MS, discussed SEER database trends in chemotherapy use for older women with TBNC and explained the rationale for using breast cancer–free survival vs OS.

Philip Blumenfeld, MD, reviewed efficacy signals from a pooled analysis of Alpha DaRT in pancreatic cancer.

Philip Blumenfeld, MD, discussed the biological rationale and distinct mechanism of action of EUS-guided radium 224 Alpha DaRT in pancreatic adenocarcinoma.

The extended-release tablet formulation may help improve patient adherence to treatment, possibly representing a more convenient, patient-friendly dosing schedule, according to Naveen Pemmaraju, MD.

At ONS 2026, an oncology nurse specialist discussed the timing and pharmacy coordination required to administer a time-sensitive mitomycin gel.

This episode of The AI Oncology Revolution highlighted the nursing and APP teams and how they are leading the charge in AI implementation.

Monthly subcutaneous amivantamab plus lazertinib shows strong first-line EGFR NSCLC responses, fewer visits, and far fewer reactions.

Learn how clinicians choose first-line EGFR lung cancer therapy, weigh brain mets risk, and manage combo side effects for lasting benefit.

At ONS 2026, Leah R. Yeager, APR, emphasized that improved internal marketing can bridge the knowledge gap and connect patients with free yoga services.

Naomi Cazeau, MSN, ANP-BC, AOCNP, discussed how anemia and inflammation drive psychoneurological symptoms in patients with hematologic malignancies.

Hua-Jay Cherng, MD, suggested molecular genotyping could replace standard R-CHOP with targeted, less toxic treatments tailored to specific DLBCL subtypes.

Properly training staff members and ensuring patient education are critical to ensuring the outpatient use of bispecific antibodies in the community setting.

Linda Chan, MSN, RN, ONC, CMSRN, EBP-C, emphasized that patients should check with providers regarding the removal of larger heparin lines for flushes.

Hua-Jay Cherng, MD, described the “threefold” benefits of taking part in training programs among junior investigators in lymphoma.

According to Timothy A. Yap, MBBS, PhD, FRCP, there is an unmet need in oncology for treating patients with CCNE1, FBXW7, and PPP2R1A genomic alterations.